Targeted protein degradation has emerged as one of the most powerful therapeutic modalities in modern drug discovery, offering the ability to eliminate disease-driving proteins that are inaccessible to conventional small-molecule inhibitors. Among the available E3 ligases, cereblon (CRBN) remains the most clinically validated and widely exploited, forming the foundation of both PROTACs and molecular glue (MG) degraders.

However, molecular glue discovery continues to face major bottlenecks, including the lack of rational design strategies and the limited chemical diversity of available E3 ligase binders. These challenges restrict the efficiency of molecular glue discovery and design, driving strong demand for new toolkits for molecular glue screening.

In this webinar, Dr. Hongbo Zhang from HitChem will introduce HitChem’s in-house CRBN molecular glue library, built from structurally diverse, experimentally validated CRBN binders.

Please scan the QR code below or click the link: https://us06web.zoom.us/webinar/register/WN_Grzo_jHVTbKKfZZU6j2dkQ   to register.